Literature DB >> 1982371

Haemorrhagic fever with renal syndrome: evaluation of ELISA for detection of Puumala-virus-specific IgG and IgM.

B Niklasson1, E Tkachenko, A P Ivanov, G van der Groen, D Wiger, H K Andersen, J LeDuc, T Kjelsson, K Nyström.   

Abstract

IgM and IgG ELISA to Puumala virus were evaluated using sera from patients with haemorrhagic fever with renal syndrome (HFRS) from different geographical regions: Sweden, Denmark, Norway, Belgium and the European USSR. IgM ELISA proved useful in the diagnosis of HFRS in patients from all the regions mentioned above. Specific IgM could be detected as early as day 1 post onset of disease, and patients remained IgM-positive for several months. Specific IgG ELISA antibodies were also frequently detected in acute sera, and acute-convalescent serum pairs often failed to show a significant titre rise or increase in optical density (OD) values. This limits the use of IgG ELISA in patient diagnosis. Sera collected 2 years after infection revealed higher IgG ELISA OD readings than convalescent sera, and very high values were still detectable 10 to 20 years postinfection. IgG ELISA is therefore useful for the testing of immunity and in seroepidemiological studies. Acute and convalescent sera from HFRS patients in Korea and the Asian USSR showed no or only very weak reactivity in the Puumala virus IgG and IgM ELISA. These results are consistent with the "one-way" crossing described earlier.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1982371     DOI: 10.1016/0923-2516(90)90036-i

Source DB:  PubMed          Journal:  Res Virol        ISSN: 0923-2516


  11 in total

1.  Seroprevalence of hantavirus antibodies in Germany as determined by a new recombinant enzyme immunoassay.

Authors:  L Zöller; M Faulde; H Meisel; B Ruh; P Kimmig; U Schelling; M Zeier; P Kulzer; C Becker; M Roggendorf
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

2.  IgG avidity assay for estimation of the time after onset of hantavirus infection in colonized and wild bank voles.

Authors:  I Gavrilovskaya; N Apekina; N Okulova; V Demina; A Bernshtein; Y Myasnikov
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

3.  Bank vole monoclonal antibodies against Puumala virus envelope glycoproteins: identification of epitopes involved in neutralization.

Authors:  A Lundkvist; B Niklasson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  Immunoglobulin G subclass responses against the structural components of Puumala virus.

Authors:  A Lundkvist; S Björsten; B Niklasson
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

5.  The humoral response to Puumala virus infection (nephropathia epidemica) investigated by viral protein specific immunoassays.

Authors:  A Lundkvist; J Hörling; B Niklasson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

6.  Detection and subsequent sequencing of Puumala virus from human specimens by PCR.

Authors:  J Hörling; A Lundkvist; K Persson; M Mullaart; T Dzagurova; A Dekonenko; E Tkachenko; B Niklasson
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

7.  Hemorrhagic fever with renal syndrome: a study of sequelae following nephropathia epidemica.

Authors:  B Niklasson; G Hellsten; J LeDuc
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

Review 8.  Haemorrhagic fever with renal syndrome, virological and epidemiological aspects.

Authors:  B S Niklasson
Journal:  Pediatr Nephrol       Date:  1992-03       Impact factor: 3.714

9.  Mapping of B-cell determinants in the nucleocapsid protein of Puumala virus: definition of epitopes specific for acute immunoglobulin G recognition in humans.

Authors:  A Lundkvist; S Björsten; B Niklasson; N Ahlborg
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

10.  Baculovirus expression of the nucleocapsid protein of a Puumala serotype Hantavirus.

Authors:  C Schuldt; L Zöller; E K Bautz; G Darai
Journal:  Virus Genes       Date:  1994-03       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.